Summary
According to APO Research, The global Gastrointestinal Therapeutics and Diagnostics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Gastrointestinal Therapeutics and Diagnostics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Gastrointestinal Therapeutics and Diagnostics include Takeda Pharmaceutical Company, Eisai, Johnson & Johnson, AstraZeneca, Salix Pharmaceuticals and Abbott Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Gastrointestinal Therapeutics and Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastrointestinal Therapeutics and Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Gastrointestinal Therapeutics and Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastrointestinal Therapeutics and Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastrointestinal Therapeutics and Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Gastrointestinal Therapeutics and Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Gastrointestinal Therapeutics and Diagnostics Segment by Company
Takeda Pharmaceutical Company
Eisai
Johnson & Johnson
AstraZeneca
Salix Pharmaceuticals
Abbott Laboratories
Gastrointestinal Therapeutics and Diagnostics Segment by Type
Diagnostics
Therapeutics
Gastrointestinal Therapeutics and Diagnostics Segment by Application
Peptic Ulcer Disease (PUD)
GI Bleeding
Gastroenteritis
Irritable Bowel Syndrome
Others
Gastrointestinal Therapeutics and Diagnostics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Therapeutics and Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Therapeutics and Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Therapeutics and Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Gastrointestinal Therapeutics and Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Gastrointestinal Therapeutics and Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal Therapeutics and Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
- Market Overview
- Product Definition
- Gastrointestinal Therapeutics and Diagnostics Market by Type
- Global Gastrointestinal Therapeutics and Diagnostics Market Size by Type, 2020 VS 2024 VS 2031
- Diagnostics
- Therapeutics
- Gastrointestinal Therapeutics and Diagnostics Market by Application
- Global Gastrointestinal Therapeutics and Diagnostics Market Size by Application, 2020 VS 2024 VS 2031
- Peptic Ulcer Disease (PUD)
- GI Bleeding
- Gastroenteritis
- Irritable Bowel Syndrome
- Others
- Assumptions and Limitations
- Study Goals and Objectives
- Gastrointestinal Therapeutics and Diagnostics Market Dynamics
- Gastrointestinal Therapeutics and Diagnostics Industry Trends
- Gastrointestinal Therapeutics and Diagnostics Industry Drivers
- Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges
- Gastrointestinal Therapeutics and Diagnostics Industry Restraints
- Global Growth Perspective
- Global Gastrointestinal Therapeutics and Diagnostics Market Perspective (2020-2031)
- Global Gastrointestinal Therapeutics and Diagnostics Growth Trends by Region
- Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
- Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2020-2025)
- Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2026-2031)
- Competitive Landscape by Players
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players (2020-2025)
- Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Players (2020-2025)
- Global Gastrointestinal Therapeutics and Diagnostics Players Revenue Share Top 10 and Top 5 in 2024
- Global Gastrointestinal Therapeutics and Diagnostics Key Players Ranking, 2023 VS 2024 VS 2025
- Global Gastrointestinal Therapeutics and Diagnostics Key Players Headquarters & Area Served
- Global Gastrointestinal Therapeutics and Diagnostics Players, Product Type & Application
- Global Gastrointestinal Therapeutics and Diagnostics Players Establishment Date
- Market Competitive Analysis
- Global Gastrointestinal Therapeutics and Diagnostics Market CR5 and HHI
- 2024 Gastrointestinal Therapeutics and Diagnostics Tier 1, Tier 2, and Tier 3
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players
- Gastrointestinal Therapeutics and Diagnostics Market Size by Type
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020 VS 2024 VS 2031)
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2020-2031)
- Gastrointestinal Therapeutics and Diagnostics Market Size by Application
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020 VS 2024 VS 2031)
- Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2020-2031)
- Company Profiles
- Takeda Pharmaceutical Company
- Takeda Pharmaceutical Company Comapny Information
- Takeda Pharmaceutical Company Business Overview
- Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- Takeda Pharmaceutical Company Recent Developments
- Eisai
- Eisai Comapny Information
- Eisai Business Overview
- Eisai Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- Eisai Recent Developments
- Johnson & Johnson
- Johnson & Johnson Comapny Information
- Johnson & Johnson Business Overview
- Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- Johnson & Johnson Recent Developments
- AstraZeneca
- AstraZeneca Comapny Information
- AstraZeneca Business Overview
- AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- AstraZeneca Recent Developments
- Salix Pharmaceuticals
- Salix Pharmaceuticals Comapny Information
- Salix Pharmaceuticals Business Overview
- Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- Salix Pharmaceuticals Recent Developments
- Abbott Laboratories
- Abbott Laboratories Comapny Information
- Abbott Laboratories Business Overview
- Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)
- Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio
- Abbott Laboratories Recent Developments
- Takeda Pharmaceutical Company
- North America
- North America Gastrointestinal Therapeutics and Diagnostics Revenue (2020-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025)
- North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031)
- United States
- Canada
- Mexico
- Europe
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue (2020-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025)
- Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031)
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Poland
- China
- China Gastrointestinal Therapeutics and Diagnostics Revenue (2020-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025)
- China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031)
- China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031)
- Asia (Excluding China)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue (2020-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025)
- Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031)
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America, Middle East and Africa
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue (2020-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025)
- SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Saudi Arabia
- Israel
- UAE
- Turkey
- Iran
- Egypt
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Table 2 | :Diagnostics Major Player |
Table 3 | :Therapeutics Major Player |
Table 4 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Table 5 | :Peptic Ulcer Disease (PUD) Major Player |
Table 6 | :GI Bleeding Major Player |
Table 7 | :Gastroenteritis Major Player |
Table 8 | :Irritable Bowel Syndrome Major Player |
Table 9 | :Others Major Player |
Table 10 | :Gastrointestinal Therapeutics and Diagnostics Industry Trends |
Table 11 | :Gastrointestinal Therapeutics and Diagnostics Industry Drivers |
Table 12 | :Gastrointestinal Therapeutics and Diagnostics Industry Opportunities and Challenges |
Table 13 | :Gastrointestinal Therapeutics and Diagnostics Industry Restraints |
Table 14 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031 |
Table 15 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2020-2025) & (US$ Million) |
Table 16 | :Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region (2020-2025) |
Table 17 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2026-2031) & (US$ Million) |
Table 18 | :Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region (2026-2031) |
Table 19 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Players (US$ Million) & (2020-2025) |
Table 20 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Players (2020-2025) |
Table 21 | :Global Gastrointestinal Therapeutics and Diagnostics Key Players Ranking, 2023 VS 2024 VS 2025 |
Table 22 | :Global Gastrointestinal Therapeutics and Diagnostics Key Players Headquarters & Area Served |
Table 23 | :Global Gastrointestinal Therapeutics and Diagnostics Players, Product Type & Application |
Table 24 | :Global Gastrointestinal Therapeutics and Diagnostics Players Establishment Date |
Table 25 | :Global Players Market Concentration Ratio (CR5 and HHI) |
Table 26 | :Global Gastrointestinal Therapeutics and Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
Table 27 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 28 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 29 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Table 30 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2020-2025) & (US$ Million) |
Table 31 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2026-2031) & (US$ Million) |
Table 32 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 33 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 34 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Table 35 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2020-2025) & (US$ Million) |
Table 36 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2026-2031) & (US$ Million) |
Table 37 | :Takeda Pharmaceutical Company Company Information |
Table 38 | :Takeda Pharmaceutical Company Business Overview |
Table 39 | :Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 40 | :Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 41 | :Takeda Pharmaceutical Company Recent Development |
Table 42 | :Eisai Company Information |
Table 43 | :Eisai Business Overview |
Table 44 | :Eisai Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 45 | :Eisai Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 46 | :Eisai Recent Development |
Table 47 | :Johnson & Johnson Company Information |
Table 48 | :Johnson & Johnson Business Overview |
Table 49 | :Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 50 | :Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 51 | :Johnson & Johnson Recent Development |
Table 52 | :AstraZeneca Company Information |
Table 53 | :AstraZeneca Business Overview |
Table 54 | :AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 55 | :AstraZeneca Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 56 | :AstraZeneca Recent Development |
Table 57 | :Salix Pharmaceuticals Company Information |
Table 58 | :Salix Pharmaceuticals Business Overview |
Table 59 | :Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 60 | :Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 61 | :Salix Pharmaceuticals Recent Development |
Table 62 | :Abbott Laboratories Company Information |
Table 63 | :Abbott Laboratories Business Overview |
Table 64 | :Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue and Gross Margin (US$ Million) & (2020-2025) |
Table 65 | :Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Product Portfolio |
Table 66 | :Abbott Laboratories Recent Development |
Table 67 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 68 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 69 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 70 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025) & (US$ Million) |
Table 71 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031) & (US$ Million) |
Table 72 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 73 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 74 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 75 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025) & (US$ Million) |
Table 76 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031) & (US$ Million) |
Table 77 | :China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 78 | :China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 79 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 80 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 81 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 82 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025) & (US$ Million) |
Table 83 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031) & (US$ Million) |
Table 84 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million) |
Table 85 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million) |
Table 86 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
Table 87 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2020-2025) & (US$ Million) |
Table 88 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Country (2026-2031) & (US$ Million) |
Table 89 | :Research Programs/Design for This Report |
Table 90 | :Authors List of This Report |
Table 91 | :Secondary Sources |
Table 92 | :Primary Sources |
List of Figures
Figure 1 | :Gastrointestinal Therapeutics and Diagnostics Image |
Figure 2 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Share 2020 VS 2024 VS 2031 |
Figure 4 | :Diagnostics Image |
Figure 5 | :Therapeutics Image |
Figure 6 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
Figure 7 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size Share 2020 VS 2024 VS 2031 |
Figure 8 | :Peptic Ulcer Disease (PUD) Image |
Figure 9 | :GI Bleeding Image |
Figure 10 | :Gastroenteritis Image |
Figure 11 | :Irritable Bowel Syndrome Image |
Figure 12 | :Others Image |
Figure 13 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size (US$ Million) & (2020-2031) |
Figure 14 | :Global Gastrointestinal Therapeutics and Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031 |
Figure 15 | :Global Gastrointestinal Therapeutics and Diagnostics Market Share by Region: 2020 VS 2024 VS 2031 |
Figure 16 | :Global Gastrointestinal Therapeutics and Diagnostics Players Revenue Share Top 10 and Top 5 in 2024 |
Figure 17 | :Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 18 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 19 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 20 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Type (2020-2031) |
Figure 21 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 22 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2020 VS 2024 VS 2031) |
Figure 23 | :Global Gastrointestinal Therapeutics and Diagnostics Revenue Market Share by Application (2020-2031) |
Figure 24 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 25 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Figure 26 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031) |
Figure 27 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Figure 28 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031) |
Figure 29 | :North America Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2020-2031) |
Figure 30 | :United States Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 31 | :Canada Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 32 | :Mexico Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 33 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 34 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Figure 35 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031) |
Figure 36 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Figure 37 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031) |
Figure 38 | :Europe Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2020-2031) |
Figure 39 | :Germany Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 40 | :France Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 41 | :U.K. Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 42 | :Italy Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 43 | :Spain Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 44 | :Russia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 45 | :Netherlands Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 46 | :Nordic Countries Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 47 | :China Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 48 | :China Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Figure 49 | :China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031) |
Figure 50 | :China Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Figure 51 | :China Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031) |
Figure 52 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 53 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Figure 54 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031) |
Figure 55 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Figure 56 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031) |
Figure 57 | :Asia Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2020-2031) |
Figure 58 | :Japan Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 59 | :South Korea Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 60 | :India Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 61 | :Australia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 62 | :Taiwan Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 63 | :Southeast Asia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 64 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (2020-2031) & (US$ Million) |
Figure 65 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million) |
Figure 66 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Type (2020-2031) |
Figure 67 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million) |
Figure 68 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Application (2020-2031) |
Figure 69 | :SAMEA Gastrointestinal Therapeutics and Diagnostics Revenue Share by Country (2020-2031) |
Figure 70 | :Brazil Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 71 | :Argentina Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 72 | :Chile Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 73 | :Colombia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 74 | :Peru Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 75 | :Saudi Arabia Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 76 | :Israel Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 77 | :UAE Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 78 | :Turkey Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 79 | :Iran Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 80 | :Egypt Gastrointestinal Therapeutics and Diagnostics Revenue YoY Growth (US$ Million) & (2020-2031) |
Figure 81 | :Years Considered |
Figure 82 | :Research Process |
Figure 83 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Gastrointestinal Therapeutics and Diagnostics Market Analysis and Forecast 2025-2031
Pages: 193
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.